These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16343062)

  • 1. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Smirne C; Caldato M; Pirisi M
    Liver Int; 2005 Dec; 25(6):1128-35. PubMed ID: 16343062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Mariuzzi L; Avellini C; Minisini R; Pirisi M
    Am J Clin Pathol; 2004 Sep; 122(3):428-33. PubMed ID: 15362374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus.
    Wozniak MA; Itzhaki RF; Faragher EB; James MW; Ryder SD; Irving WL;
    Hepatology; 2002 Aug; 36(2):456-63. PubMed ID: 12143056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C.
    Toniutto P; Fabris C; Falleti E; Cussigh A; Fontanini E; Bitetto D; Fornasiere E; Minisini R; De Feo T; Marangoni F; Pirisi M
    Liver Int; 2008 Feb; 28(2):257-63. PubMed ID: 17900242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression.
    Alkhouri N; Hanouneh IA; Lopez R; Zein NN
    Liver Transpl; 2010 Feb; 16(2):155-62. PubMed ID: 20104483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
    Neumann UP; Berg T; Bahra M; Seehofer D; Langrehr JM; Neuhaus R; Radke C; Neuhaus P
    J Hepatol; 2004 Nov; 41(5):830-6. PubMed ID: 15519657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Fornasiere E; Smirne C; Pirisi M
    J Gastroenterol; 2007 Jul; 42(7):543-9. PubMed ID: 17653650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.
    Vaisi-Raygani A; Rahimi Z; Nomani H; Tavilani H; Pourmotabbed T
    Clin Biochem; 2007 Oct; 40(15):1150-6. PubMed ID: 17689519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression.
    Toniutto P; Minisini R; Fabris C; De Feo T; Marangoni F; Burlone M; Avellini C; Bitetto D; Fornasiere E; Fumolo E; Baccarani U; Pirisi M
    Clin Transplant; 2009; 23(2):184-90. PubMed ID: 19210526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of 49245A>G (rs868) polymorphism in the 3'UTR of donor TGFBR1 gene with course of hepatitis C following orthotopic liver transplantation.
    Ziarkiewicz-Wróblewska B; Sajjad E; Ciszek M; Hutnik Ł; Łukasik D; Fedorowicz M; Wróblewski T; Patkowski W; Pączek L; Płoski R; Włodarski P; Malejczyk J
    Ann Transplant; 2014 Dec; 19():643-51. PubMed ID: 25502482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.
    Toniutto P; Fabris C; Avellini C; Minisini R; Bitetto D; Rossi E; Smirne C; Pirisi M
    World J Gastroenterol; 2005 Oct; 11(38):5944-50. PubMed ID: 16273604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation.
    Toniutto P; Fabris C; Bortolotti N; Minisini R; Avellini C; Fumo E; Pirisi M
    J Hepatol; 2004 Aug; 41(2):307-11. PubMed ID: 15288481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
    Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
    J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.
    Rigamonti C; Donato MF; Fraquelli M; Agnelli F; Ronchi G; Casazza G; Rossi G; Colombo M
    Gut; 2008 Jun; 57(6):821-7. PubMed ID: 18218676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.
    Machicao VI; Bonatti H; Krishna M; Aqel BA; Lukens FJ; Nguyen JH; Rosser BG; Satyanarayana R; Grewal HP; Hewitt WR; Harnois DM; Crook JE; Steers JL; Dickson RC
    Transplantation; 2004 Jan; 77(1):84-92. PubMed ID: 14724440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation.
    Arenas JI; Gallegos-Orozco JF; Laskus T; Wilkinson J; Khatib A; Fasola C; Adair D; Radkowski M; Kibler KV; Nowicki M; Douglas D; Williams J; Netto G; Mulligan D; Klintmalm G; Rakela J; Vargas HE
    J Infect Dis; 2004 Jun; 189(11):2037-46. PubMed ID: 15143471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.